As the hunt for skilled employees in China intensifies, pharmaceutical group Sanofi is using artificial intelligence to identify the most promising and loyal applicants.
“We are facing a very fierce talent war, not just from multinationals but from a lot of Chinese companies that want to expand,” says Iris Zhou, head of talent acquisition for Asia Pacific.
Sanofi has been using an algorithm for the past two years to assess interns on their potential cultural fit with the organisation. Only then are the shortlisted candidates interviewed by HR staff.
> Read the full article on the Financial Times website
By Andrew Jack
Source: Financial Times
In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.
Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).
In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.
